Platelet Cyclic Guanosine Monophosphate as a Biomarker of Phosphodiesterase Type 5 Inhibitor Efficacy in the Treatment of Erectile Dysfunction: A Randomized Placebo-Controlled Study

European Urology

Volumn 56, Issue 6, 2009, Pages 1067-1073

  Mirone, Vincenzo ^a   d'Emmanuele di Villa Bianca, Roberta ^a   Mitidieri, Emma ^a   Imbimbo, Ciro ^a   Fusco, Ferdinando ^a   Verze, Paolo ^a   Vitale, Dino F ^b   Sorrentino, Raffaella ^a   Cirino, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS   (Italy)

Author keywords

cGMP; Erectile dysfunction; Platelet; Vardenafil; VASP

Indexed keywords

BIOLOGICAL MARKER; CYCLIC GMP; VARDENAFIL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SCORING SYSTEM; SEXUAL BEHAVIOR; THROMBOCYTE; TREATMENT DURATION; VISUAL STIMULATION;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD PLATELETS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PLACEBOS; REPRODUCIBILITY OF RESULTS; SULFONES; TRIAZINES; YOUNG ADULT;

EID: 70350571170     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.09.031     Document Type: Article

References (24)

1. Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., and Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830
2. Souverein P.C., Egberts A.C., Meuleman E.J., Urquhart J., and Leufkens H.G. Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res 14 (2002) 259-265
3. Ströberg P., Murphy A., and Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 25 (2003) 2724-2737
4. Rubio-Aurioles E., Porst H., Eardley I., Goldstein I., and Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 3 (2006) 1037-1049
5. Moncada I., Jara J., Subirá D., Castaño I., and Hernández C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 46 (2004) 357-361
6. Young J.M., Feldman R.A., Auerbach S.M., et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. J Androl 26 (2005) 310-318
7. Shabsigh R., Seftel A.D., Rosen R.C., et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology 68 (2006) 689-696
8. Blount M.A., Beasley A., Zoraghi R., et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66 (2004) 144-152
9. Yang C.C., Porter M.P., and Penson D.F. Comparison of the International Index of Erectile Function erectile domain score and nocturnal penile tumescence and rigidity measurements: does one predict the other?. BJU Int 98 (2006) 105-109
10. Melman A., Fogarty J., and Hafron J. Can self-administered questionnaires supplant objective testing of erectile function? A comparison between the International Index of Erectile Function and objective studies. Int J Impot Res 18 (2006) 126-129
11. Giuliano F. Mechanism of action of PDE5 inhibitors in LUTS and ED: the NO-cGMP pathway. Eur Urol 55 (2009) 49-51
12. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75 (1995) 725-748
13. Wallis R.M., Corbin J.D., Francis S.H., and Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83 (1999) 3C-12C
14. Dunkern T.R., and Hatzelmann A. The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal 17 (2005) 331-339
15. Keefer L.K., Nims R.W., Davies K.M., et al. NONOates" (1-substituted diazen-1-ium-1, 2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol 268 (1996) 281-293
16. Minamiyama Y., Takemura S., Hai S., Suehiro S., and Okada S. Vitamin E deficiency accelerates nitrate tolerance via a decrease in cardiac P450 expression and increased oxidative stress. Free Radic Biol Med 40 (2006) 808-816
17. Montorsi F., Brock G., Lee J., et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 54 (2008) 924-931
18. De Young L.X., Domes T., Lim K., Carson J., and Brock G.B. Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 54 (2008) 213-220
19. Carson C.C., Hatzichristou D.G., Carrier S., et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 94 (2004) 1301-1309
20. Mizuno I., Fuse H., Fujiuchi Y., Nakagawa O., and Akashi T. Comparative study between audiovisual sexual stimulation test and nocturnal penile tumescence test using RigiScan Plus in the evaluation of erectile dysfunction. Urol Int 72 (2004) 221-224
21. Oelze M., Mollnau H., Hoffmann N., et al. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 87 (2000) 999-1005
22. Klotz T., Sachse R., Heidrich A., et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 19 (2001) 32-39
23. Gupta M., Kovar A., and Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45 (2005) 987-1003
24. Francis S.H., Morris G.Z., and Corbin J.D. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 20 (2008) 333-342